MACH32 INC.
$30,000.00 CAD
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2024-2025
- Agreement period
- June 1, 2024 – February 28, 2025
- Reference
- nrc-cnrc:172-2024-2025-Q1-1018592
Published purpose
MACH32 is developing a drug-device combination medical product for early intervention and treatment of severe hemorrhage. This device administers a large-volume dose of the antifibrinolytic drug tranexamic acid (TXA). It simplifies the delivery of TXA, a clinically proven generic drug that reduces the risk of death due to bleeding by ~ 30%. TXA is underused because it is difficult to deliver and requires intravenous access; less than 5% of eligible patients receive TXA in a timely manner. This project focuses on the development of a highly concentrated TXA formulation optimized for simple intramuscular delivery in autoinjector format.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.